Infectofos

Fosfomycin Sodium, the active ingredient in Infectofos, is a phosphonic acid antibiotic presented as an intravenous solution for intravenous use. It is employed to treat serious bacterial infections caused by susceptible Gram‑negative and Gram‑positive pathogens, particularly in hospitalized patients requiring parenteral therapy. The drug is administered under medical supervision and is indicated for infections such as complicated urinary tract infection, intra‑abdominal infection, and severe skin and soft‑tissue infection when oral options are unsuitable.

GNH USA supplies Infectofos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Infectofos (fosfomycin sodium) is used for the treatment of infections caused by susceptible bacteria, especially within the urinary, intra‑abdominal and skin‑soft tissue categories.

- Complicated urinary tract infection: effective against Gram‑negative uropathogens, reducing bacterial load. - Complicated intra‑abdominal infection: provides broad‑spectrum coverage for mixed aerobic and anaerobic organisms. - Severe skin and soft‑tissue infection: helps eradicate resistant Staphylococcus and Streptococcus species. - Bacteremia/sepsis: used as part of combination therapy for systemic infections when rapid bacterial eradication is needed.

Adverse reactions may occur with any medication. The following lists have been reported for intravenous fosfomycin.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Infusion site reactions: erythema, pain or phlebitis at the injection site.

Serious or Rare Side Effects: - Hypersensitivity reactions: including anaphylaxis, rash or angioedema. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Renal impairment: acute kidney injury, especially with concomitant nephrotoxic drugs. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Electrolyte disturbances: hypernatremia or hypokalemia in susceptible patients.

Prior to initiating therapy, clinicians should consider several safety aspects.

- Renal function: assess baseline creatinine and adjust dosing in severe impairment. - Hypersensitivity: discontinue immediately if an allergic reaction occurs. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Concomitant nephrotoxic agents: monitor renal parameters closely when combined with aminoglycosides or loop diuretics. - Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Fosfomycin may interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity when co‑administered. - Loop diuretics: may potentiate ototoxic effects. - Anticoagulants (e.g., heparin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Probenecid: can reduce fosfomycin clearance, raising plasma levels. - Warfarin: monitor INR as fosfomycin may alter anticoagulant effect. - Oral contraceptives: potential reduction in hormonal efficacy, advise additional contraceptive measures.